Top

Virology Journal

Published in:

Open Access 01-12-2011 | Research

Prohibitin is overexpressed in Huh-7-HCV and Huh-7.5-HCV cells harboring in vitro transcribed full-length hepatitis C virus RNA

Authors: Shuang-Suo Dang, Ming-Zhu Sun, E Yang, Meng Xun, Li Ma, Zhan-Sheng Jia, Wen-Jun Wang, Xiao-Li Jia

Published in: Virology Journal | Issue 1/2011

Abstract

Background

Currently, up-regulated proteins and apoptosis in hepatitis C is a hot topic in exploring the pathogenic mechanism of Heptitis C Virus(HCV). Some recent studies shows that prohibitin is overexpressed in cells expressing HCV core proteins, and up-regulated prohibitin is also found in human hepatoma cell line HCC-M, lung cancer, prostate cancer, and other cancers. Prohibitin is an important member of the membrane protein superfamily, and it plays a role of molecular chaperones in mitochondrial protein stability. Meanwhile, it has a permissive action on tumor growth or acts as an oncosuppressor. Based on our previously established the in vitro HCV cell-culture system (HCVcc), here we aimed to investigate the different expression profiles of prohibitin in Huh-7-HCV and Huh-7.5-HCV cells

Methods

The total cellular RNA of Huh-7, Huh-7.5, Huh-7-HCV and Huh-7.5-HCV cells were extracted, and then the first-strand cDNA was reversely transcribed. The expression of prohibitin at the mRNA level was assessed by real-time PCR with GAPDH as the control. Furthermore, the expression of prohibitin at the protein level was evaluated by western blot with GAPDH as an internal control.

Results

Our results of real-time PCR showed that the mRNA expression level of prohibitin in Huh-7-HCV cells was 2.09 times higher than that in Huh-7 cells, while, the mRNA level of prohibitin in Huh-7.5-HCV cells was 2.25 times higher than that in Huh-7.5 cells. The results of western blot showed that the protein expression level of prohibitin in Huh-7-HCV cells was 2.38 times higher than that in Huh-7 cells, while the protein expression of prohibitin in Huh-7.5-HCV cells was 2.29 times higher than that in Huh-7.5 cells.

Conclusions

The expression of prohibitin was relatively high in Huh-7-HCV and Huh-7.5-HCV cells harboring in vitro transcribed full-length HCV RNA.

Available only for authorised users

Lee JH, Lee S, Park MY, Myung H: Characterization of thiobarbituric acid derivatives as inhibitors of hepatitis C virus NS5B polymerase. Virol J 2011, 14: 8-18.

Bobeck DR, Schinazi RF, Coats SJ: Advances in nucleoside monophoaphate prodrugs as anti-HCV agents. Antivir Ther 2010,15(7):935-50. 10.3851/IMP1667CrossRefPubMed

Javed T, Ashfaq UA, Riaz S, Rehman S, Riazuddin S: In-vitro antiviral activity of Solanum nigrum against Hepatitis C Virus. Virol J 2011, 19: 8-26.

Bamaba V: Hepatitis C virus infection: a "liasion a trois" amongst the virus, the host, and chronic low-level inflammation for human survival. J Hepatol 2010,53(4):752-61. 10.1016/j.jhep.2010.06.003CrossRef

Lemon SM, Mckeating JA, Pietschmann T, Frick DN, Glenn JS, Tellinghuisen TL, Symons J, Furman PA: Development of novel therapies for hepatitis C. Antiviral Res 2010,86(1):79-92. 10.1016/j.antiviral.2010.02.003CrossRefPubMed

Foster GR: Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b. Drugs 2010,70(2):147-65. 10.2165/11531990-000000000-00000CrossRefPubMed

Sanchez-Quiles V, Santamaria E, Segura V, Sesma L, Prieto J, Corrales FJ: Prohibitin deficiency blocks proliferation and induces apoptosis in human hepatoma cells: Molecular mechanisms and functional implications. Proteomics 2010,10(8):1609-20. 10.1002/pmic.200900757CrossRefPubMed

Peng X, Mthta R, Wang S, Chellappan S, Mthta RG: Prohibitin is a novel target gene of vitamin D involved in its antiproliferative action in breast cancer cells. Cancer Res 2006,66(14):7361-9. 10.1158/0008-5472.CAN-06-1004CrossRefPubMed

Rizwani W, Alexandrow M, Chellappan S: Prohibitin physically interacts with MCM proteins and inhibits mammalian DNA replication. Cell Cycle 2009, 8: 1621-1629. 10.4161/cc.8.10.8578PubMedCentralCrossRefPubMed

10.

Woodlock TJ, Bethlendy G, Segel GB: Prohibitin expression is increased in phorbol ester-treated chronic leukemic B-lymphocytes. Blood Cells Mol Dis 2001, 27: 27-34. 10.1006/bcmd.2000.0348CrossRefPubMed

11.

Mengwasser J, Piau A, Schlag P, Sleeman JP: Differential immunization identifies PHB1/PHB2 as blood-borne tumor antigens. Oncogene 2004, 23: 7430-7435. 10.1038/sj.onc.1207987CrossRefPubMed

12.

Tsai HW, Chow NH, Lin CP, Chan SH, Chou CY, Ho CL: The significance of prohibitin and c-Met/hepatocye growth factor receptor in the progression of cervical adenocarcinoma. Hum Pathol 2006, 37: 198-204. 10.1016/j.humpath.2005.10.012CrossRefPubMed

13.

Kang X, Zhang L, Sun J, Ni Z, Ma Y, Chen X, Sheng X, Chen T: Prohibitin: a potential biomarker for tissue-based detection of gastric cancer. J Gastroenterol 2008, 43: 618-625. 10.1007/s00535-008-2208-3CrossRefPubMed

14.

Nan Y, Yang S, Tian Y, Zhang W, Zhou B, Bu L, Huo S: Analysis of the expression protein profiles of lung squamous carcinoma cell using shot-gun proteomics strategy. Med Oncol 2009, 26: 215-221. 10.1007/s12032-008-9109-4CrossRefPubMed

15.

Tsutsumi T, Matsuda M, Aizaki H, Moriya K: Proteomics analysis of mitochondrial proteins reveals overexpression of a mitochondrial protein chaperon, prohibitin, in cells expressing hepatitis C virus core protein. Hepatology 2009,50(2):378-86. 10.1002/hep.22998CrossRefPubMed

16.

Sato T, Saito H, Swensen J, Olifant A, Wood C, Danner D, Sakamoto T, Takita K, Kasumi F, Miki Y: The human prohibitin gene located on chromosome 17q21 is mutated in sporadic breaset cancer. Cancer Res 1992, 52: 1643-1646.PubMed

17.

Mishra S, Murphy LC, Murphy LJ: The prohibitins: emerging roles in diverse functions. J Cell Mol Med 2006, 10: 353-363. 10.1111/j.1582-4934.2006.tb00404.xPubMedCentralCrossRefPubMed

18.

Rastogi S, Joshi B, Dasgupta P, Morris M, Wright K, Chellappan S: Prohibitin facilitates cellular senescence by recruiting specific corepressors to inhibit E2F target genes. Mol Cell Biol 2006, 26: 4161-4171. 10.1128/MCB.02142-05PubMedCentralCrossRefPubMed

19.

Fusaro G, Dasgupta P, Rastogi S, Joshi B, Chellappan S: Prohibitin induces the transcriptional activity of p53 and is exported from the nucleus upon apoptotic signaling. J Biol Chem 2003, 278: 47853-47861. 10.1074/jbc.M305171200CrossRefPubMed

20.

Joshi B, Ko D, Ordonez-Ercan D, Chellappan SP: A putative coiled-coil domain of prohibitin is sufficient to repress E2F1-mediated transcription and induce apoptosis. Biochem Biophys Res Commun 2003, 312: 459-466. 10.1016/j.bbrc.2003.10.148CrossRefPubMed

21.

Jupe ER, Liu XT, Kiehlbauch JL, McClung JK, Dell'Orco RT: The 3' untranslated region of prohibitin and cellular immortalization. Exp Cell Res 1996, 224: 128-135. 10.1006/excr.1996.0120CrossRefPubMed

22.

Gamble SC, Odontiadis M, Waxm an J: Androgens target prohibitn to regulate proliferation of prostate cancer cells. Oncogene 2004, 23: 2996-3004. 10.1038/sj.onc.1207444CrossRefPubMed

23.

Seow TK, Ong SE, Liang RC, Ren EC, Chan L, Ou K, Chung MC: Two-dimensional electrophoresis map of the human hepatocellular carcinoma cell line, HCC-M, and identification of the separated proteins by mass spectrometry. Electrophoresis 2000, 21: 1787-1813. 10.1002/(SICI)1522-2683(20000501)21:9<1787::AID-ELPS1787>3.0.CO;2-ACrossRefPubMed

Title: Prohibitin is overexpressed in Huh-7-HCV and Huh-7.5-HCV cells harboring in vitro transcribed full-length hepatitis C virus RNA
Authors: Shuang-Suo Dang
Ming-Zhu Sun
E Yang
Meng Xun
Li Ma
Zhan-Sheng Jia
Wen-Jun Wang
Xiao-Li Jia
Publication date: 01-12-2011
Publisher: BioMed Central
Published in: Virology Journal / Issue 1/2011
Electronic ISSN: 1743-422X
DOI: https://doi.org/10.1186/1743-422X-8-424

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2011

Hepatitis C virus genotypes in Pakistan: a systemic review

The characteristics of the synonymous codon usage in hepatitis B virus and the effects of host on the virus in codon usage pattern

Frequency distribution of HCV genotypes among chronic hepatitis C patients of Khyber Pakhtunkhwa

Herpes simplex virus type 2 infection increases human immunodeficiency virus type 1 entry into human primary macrophages

Human Papillomavirus in Brazilian women with and without cervical lesions

Identification of critical residues of influenza neuraminidase in viral particle release

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials